Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Alnylam Pharmaceuticals Inc (ALNY.O)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (US$) Price Target (US$) Rating
2022-03-30165.24211.00Buy
2022-05-19129.36204.00Buy
2022-08-11229.39-No Rating
2022-08-17223.13266.00Buy
2023-08-04185.58256.00Buy
2023-10-23162.00253.00Buy
2024-06-28243.00288.00Buy
2024-08-16268.24308.00Buy
2024-11-01273.91310.00Buy
2025-02-14256.45331.00Buy
2025-05-02259.39349.00Buy
2025-06-18312.32398.00Buy

Disclosures

  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.